Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MORF Morphic (MORF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends About Morphic Stock (NASDAQ:MORF) 30 days 90 days 365 days Advanced Chart Ad Chaikin Analytics320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are already moving their money… and preparing for even stranger days ahead. Over 320 hedge funds have quietly sold THIS famous stock – to prepare for a dramatic market shiftGet the strange truth from a 50-year Wall Street insider… including the name and ticker of the stock Get Morphic alerts:Sign Up Key Stats Today's Range$56.99▼$56.9950-Day Range$55.74▼$56.9952-Week Range$19.34▼$57.00Volume400 shsAverage Volume1.27 million shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/APrice Target$54.25Consensus RatingHold Company OverviewMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More… 320 hedge funds just sold this stock (Ad)320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are already moving their money… and preparing for even stranger days ahead. Over 320 hedge funds have quietly sold THIS famous stock – to prepare for a dramatic market shiftGet the strange truth from a 50-year Wall Street insider… including the name and ticker of the stock Morphic Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks28th Percentile Overall ScoreMORF MarketRank™: Morphic scored higher than 28% of companies evaluated by MarketBeat, and ranked 853rd out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingMorphic has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphic has only been the subject of 4 research reports in the past 90 days.Read more about Morphic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($4.07) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Morphic's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MORF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.57 Short InterestThere is no current short interest data available for MORF. News and Social MediaN/ANews SentimentN/A Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,018,566.00 in company stock.Percentage Held by Insiders25.60% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Morphic's insider trading history. Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address MORF Stock News HeadlinesEli Lilly acquires Morphic in IBD portfolio expansionAugust 19, 2024 | finance.yahoo.comMORF Jan 2025 25.000 put (MORF250117P00025000)August 17, 2024 | finance.yahoo.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.October 6, 2024 | Chaikin Analytics (Ad)Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel DiseaseAugust 16, 2024 | prnewswire.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAugust 8, 2024 | globenewswire.comMorphic Holding (MORF) Earnings Dates & ReportsAugust 6, 2024 | investing.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAugust 2, 2024 | globenewswire.comMorphic Holding Inc MORFJuly 31, 2024 | morningstar.comSee More Headlines MORF Stock Analysis - Frequently Asked Questions How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) issued its quarterly earnings data on Thursday, July, 25th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.19. When did Morphic IPO? Morphic (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA) and Clovis Oncology (CLVS). Company Calendar Last Earnings7/25/2024Today10/06/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$54.25 High Stock Price Target$57.00 Low Stock Price Target$46.00 Potential Upside/Downside-4.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,100,000.00 Net MarginsN/A Pretax Margin-29,119.96% Return on Equity-26.62% Return on Assets-25.74% Debt Debt-to-Equity RatioN/A Current Ratio24.13 Quick Ratio24.13 Sales & Book Value Annual Sales$520,000.00 Price / Sales5,490.11 Cash FlowN/A Price / Cash FlowN/A Book Value$12.31 per share Price / Book4.63Miscellaneous Outstanding Shares50,094,000Free Float37,270,000Market Cap$2.85 billion OptionableOptionable Beta1.49 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:MORF) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Morphic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.